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estimates obtained with network meta-analysis
of survival curves to inform decision-making
Shannon Cope1* and Jeroen P Jansen2Abstract
Background: Increasingly, network meta-analysis (NMA) of published survival data are based on parametric survival
curves as opposed to reported hazard ratios to avoid relying on the proportional hazards assumption. If a Bayesian
framework is used for the NMA, rank probabilities associated with the alternative treatments can be obtained, which
directly support decision-making. In the context of survival analysis multiple treatment effect measures are available
to inform the rank probabilities.
Methods: A fractional polynomial NMA of overall survival in advanced melanoma was performed as an illustrative
example. Rank probabilities were calculated and presented for the following effect measures: 1) median survival;
2) expected survival; 3) mean survival at the follow-up time point of the trial with the shortest follow-up; 4) hazard
or hazard ratio over time; 5) cumulative hazard or survival proportions over time; and 6) mean survival at subsequent
time points. The advantages and disadvantages of the alternative measures were discussed.
Results: Since hazard and survival estimates may vary over time for the compared interventions, calculations of rank
probabilities for an NMA of survival curves may depend on the effect measure. With methods 1–3 rank probabilities do
not vary over time, which are easier to understand and communicate than rank probabilities that vary over time as
obtained with methods 4–6. However, rank probabilities based on methods 4–6 provide useful information regarding
the relative treatment effects over time.
Conclusions: Different approaches to summarize results of a NMA of survival curves with rank probabilities have
pros and cons. Rank probabilities of treatment effects over time provide a more transparent and informative
approach to help guide decision-making than single rank probabilities based on collapsed measures, such as
median survival or expected survival. Rank probabilities based on survival proportions are the most intuitive and
straightforward to communicate, but alternatives based on the hazard function or mean survival over time may
also be useful.
Keywords: Network meta-analysis, Rank, Probabilities, SurvivalBackground
Randomized controlled trials (RCTs) are often used to
inform healthcare decisions [1-4]. In the absence of a
head-to-head or direct comparison, indirect treatment
comparisons provide a useful alternative [2,5-9]. An evidence
base that consist of multiple RCTs where each trial has at
least one intervention in common with another can be
synthesized by means of a network meta-analysis (NMA).* Correspondence: scope@mapigroup.com
1Mapi Group, 33 Bloor Street East, Suite 1300, Toronto M4W 3H1, Canada
Full list of author information is available at the end of the article
© 2013 Cope and Jansen; licensee BioMed Ce
Creative Commons Attribution License (http:/
distribution, and reproduction in any mediumThis method provides pooled estimates of available direct
comparisons, indirect comparisons of pairwise contrasts
for which no head-to-head RCT is available, and a synthesis
of consistent direct and indirect evidence, resulting in more
precise treatment effect estimates [3,10]. NMAs provide
a comprehensive synthesis of the evidence from RCTs
for multiple treatments useful for decision-makers to
assess whether a new treatment should be adopted or
whether additional evidence is required in the presence
of uncertainty [11].ntral Ltd. This is an open access article distributed under the terms of the
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tist or a Bayesian framework. The result of a frequentist
meta-analysis comparing treatments A and B is an estimate
of the treatment effect (i.e. difference between A and B) as
well as an associated p-value. The p-value indicates whether
the results are statistically ‘significant’ or ‘non-significant’.
If results are significant, the probability of erroneously
rejecting the null hypothesis is judged to be small enough
given the observed data. For example, if treatment A is
considered significantly better than treatment B then the
difference between the treatments is considered extreme
enough to suggest that there is only a small probability
(<5%) of incorrectly rejecting the null hypothesis. Therefore
the p value reflects the probability of observing such a
treatment difference assuming the null hypothesis is true.
However, decision-makers are interested in minimizing the
risk of an unsupported positive interpretation as well as
the risk of overlooking a true difference. In other words,
probabilities associated with the alternative hypothesis (i.e.
A is better than B) are of interest but cannot be deduced
from a frequentist analysis. Moreover, for an analysis
of more than two treatments, p values resulting from a
frequentist analysis associated with each pairwise com-
parison do not provide a straightforward interpretation of
the relative efficacy or safety of the alternative interventions
for decision-makers.
By using a Bayesian NMA it is possible to calculate the
probability of being the best treatment out of all those
treatments assessed with respect to the outcome of interest.
This approach combines a prior probability distribution
(representing a prior belief of the possible values for
parameter) with a likelihood distribution of the observed
effect, resulting in a posterior probability distribution [12].
With Monte Carlo simulations the probability that a
treatment is best is calculated based on the proportion of
cycles during the sampling process where a treatment
ranks first of out all the treatments included in terms
of the treatment effect size [13]. Similarly, it is possible
to calculate the probability of being the second best
treatment, third best treatment, etc., up until the prob-
ability of being worst treatment out of those assessed.
These probability statements offer an intuitive summary
of the joint posterior distribution of the effect sizes for
all the included treatments, which naturally facilitates
decision-making [13].
Salanti et al. have proposed several methods to present
rank probabilities of treatments. Given the challenge of
efficiently summarizing results from an analysis involving
multiple pairwise comparisons, probabilities are positioned
as a useful alternative to ‘p values’ resulting from a
frequentist analysis. The importance of presenting a
complete overview of the probabilities associated with each
ranking is emphasized to avoid the over-interpretation of
the probabilities associated with being the ‘best’ treatment,which necessitates a more comprehensive approach to
present the information. Therefore, several different
approaches are proposed by Salanti et al. to summarize
the probabilities in a clear a concise manner. However,
all of the methods implicitly assume that the treatment
effects are constant over time [13].
In many RCTs the endpoint of interest is the time to the
occurrence of a certain event, such as time to progression,
progression-free survival, or overall survival. The synthesis
of published results across different studies by means of
an NMA is typically based on the constant hazard ratio
(HR). However, it has been recognized that an NMA that
relies on the proportional hazards assumption is biased
if the survival curves or hazard functions of competing
interventions cross [14-17]. Recently NMA models for
survival data have been presented that do not assume a
constant HR but allow the relative treatment effects to vary
over time [14-16]. Such analyses can result in time-varying
HRs, survival proportions over time, and expected survival
by treatment. In order to apply the methods proposed
by Salanti et al. to these analyses it is important to
acknowledge that treatment effects may vary over time.
In this paper we discuss alternative approaches to
present rank probabilities in the context of a Bayesian




As an illustrative example the efficacy of systemic chemo-
therapy for advanced unresectable melanoma was assessed
in terms of overall survival. Ten RCTs were included in
the network of evidence (Figure 1) [18-27], which were
identified with a systematic review of the literature. The
treatments were categorized as dacarbazine monotherapy
(DTIC), DTIC + Interferon (DTIC+ IFN), DTIC + non-IFN,
and Non-DTIC. Although the most recent treatments
are not included, the analysis provides a useful example
in oncology, where parametric survival analyses are often
utilized.
Network meta-analysis
The available survival data of the different studies was
combined by means of a Bayesian NMA of parametric
survival curves with models proposed by Jansen 2011
[15]. With this approach the survival of patients in a trial
for the interventions being compared are modeled over
time with parametric survival functions and the difference
in the shape and scale parameters of these functions
between interventions are synthesized and indirectly
compared across trials. Within the Bayesian framework,
analyses consist of data, likelihood, parameters, and a
model. The data was extracted from the included RCTs,
where for each arm the reported Kaplan Meier curves
DTIC=dacarbazine; DTIC+IFN=dacarbazine plus Interferon; DTIC+non-IFN=dacarbazine plus non-
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Figure 1 Network of randomized controlled trials.
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http://www.biomedcentral.com/1471-2288/13/147were digitized (DigitizeIt v1.6.1). A binomial likelihood
distribution was used for the incident number of deaths
for every two month interval, which was calculated based
on the survival percentages from the Kaplan-Meier curves
and the number of patients at risk at the beginning of the
interval in each arm of each study, assuming a constant
hazard rate within each interval (see Jansen and Cope [16]
for more details). A two parameter Weibull NMA model
was used with a random effect on the scale parameter
[14-17] (See Additional file 1 for model details). Non-
informative prior distributions were used for the model
parameters to avoid influencing the results of the analysis
based on prior beliefs. The parameters were estimated
using a Markov Chain Monte Carlo within WinBUGS
software [28], where inferences were based on 30,000
iterations from two chains and the first 30,000 iterations
were discarded as ‘burn-in’.
Results
Treatment effects and functional estimates
Relative treatment effects of each intervention versus DTIC
were expressed as HRs over time defined as:
HRAk tð Þ ¼ exp

d0Ak þ d1Ak ln tð Þ

ð1Þ
where HRAk(t) is the HR of intervention k relative to A (i.e.
DTIC), and d0Ak and d1Ak are the differences in scale and
shape of treatment k relative to A as obtained with the
NMA.
In order to estimate the hazard and cumulative hazard
function by treatment, the pooled differences in scale and
shape were added to an average scale and shape for DTIC
(obtained from the DTIC studies included in the NMA).These scale and shape estimates describe the hazard over
time, as presented in Figure 2A. The ratio of hazard
curves over time reflects the HRs, which are illustrated in
Figure 2B, including the 95% credible intervals (dotted
lines). The hazards (or HRs) were fairly constant over
time, with some variation in the early months. The hazard
over time for each treatment was transformed into
survival functions as presented in Figure 3. Based on
the survival functions, the median survival (i.e. time
point where 50% of patients are still alive) as well as
the expected survival (i.e. mean survival based on the
area under the curve up to the time-point when all of
the patients have died) were estimated. The area under
the survival curve at the left of each time point represents
the mean survival up until the corresponding follow-up
time. This represents a summary measure of survival
which does not require the curves to be fully extrapolated
(i.e. up until when all patients have died). In the current
evidence network, the mean survival at 22 months was
assessed, which reflected the shortest follow-up across the
studies, i.e. the DTIC arm in the study by Middleton et al.
2000. The median survival, mean survival at 22 months,
and the expected survival are presented in Table 1.
Graphical and numerical summaries of rank probabilities
The ranking for all four treatments according to the prob-
ability of being the 1st, 2nd, 3rd, and 4th best treatments
was assessed on the basis of each of the aforementioned
effect measures.
Rankograms, presenting the probability per rank for
each treatment, are illustrated in Figure 4 for the time
independent treatment effects, including median survival,
expected survival, and mean survival at 22 months of













































Figure 2 Hazard for each treatment over time (A), and Hazard ratio for each treatment versus DTIC over time (B).
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hazard (ratio), survival proportions, and mean survival.
The rankograms for the time-independent measures
were fairly similar with some minor differences, suggesting
DTIC + non-IFN and non-DTIC tended to have the highest
probabilities of being the best and second best treatments.
DTIC generally had the highest probability of being third
best, and DTIC + IFN usually had the highest probability
of being the worst. The rankograms for median survival(Figure 4A) and expected survival (Figure 4B) were mostly
comparable (with a slight tradeoff between treatment
ranks 3 and 4 for DTIC and DTIC + IFN), whereas the
rankogram based on the mean survival at 22 months
(Figure 4C) differed because the survival curves
crossed at about 17 months for non-DTIC and DTIC +
non-IFN.
The time-dependent measures were generally comparable

















DTIC Median= 7.8 months
DTIC+IFN Median= 7.9 months
DTIC+Non-IFN Median= 9.9 months
Non-DTIC Median= 10.2 months
Median survival
Expected survival (area under survival curve)
Mean survival (area under survival curve) up until 22 months
Figure 3 Survival proportions for each treatment over time.
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ments, followed by DTIC and DTIC + IFN. Variation
in the hazard in the initial period is most obvious in
Figure 5A, where the probability of being the best treat-
ment is based on the HR. This indicates that non-DTIC is
the best treatment for the first 5 months, after which time
DTIC + non-IFN is the best treatment. The rankograms
based on the survival proportions (Figure 5B) were similar
to those based on the hazards, although the decrease in
the probability of DTIC + IFN being the best (and second
best) was less dramatic with the former. Rankograms
based on the mean survival over time were also similar
to those based on HRs and survival proportions, where
results for DTIC differed the most which remained more
consistent over time with respect to the probability of best
and second best. Similarly rankograms for non-DTIC based
on the mean survival were less sensitive to differences
over time.
Another measure to summarize probabilities proposed
by Salanti et al. [13] is the surface under the cumulative
ranking curve (SUCRA), which provides a summary statis-
tic for the cumulative ranking. SUCRA ranges from 0 to 1,
where 1 reflects the best treatment with no uncertainty
and 0 reflects the worst treatment with no uncertainty.Table 1 Overview of time-independent summary measures
Outcome DTIC
Median survival 7.85
Expected survival (after all patients died)
and 95% credible interval
12.61 (11.31, 14.13)
Mean survival at 22 months and
95% credible interval
9.84 (9.13, 10.60)SUCRA for treatment k out of competing interventions a
can be expressed as follows based on a vector of cumulative







SUCRA was assessed for all effect measures for each
treatment. In order to emphasize the importance of
assessing SUCRA, probabilities of being the best treat-
ment are compared to the SUCRA scores. Figures 6 and 7
present the probability that each treatment is best as well
as SUCRA for the time-independent and time-dependent
measures.
Figure 6 illustrates that the pattern associated with the
probability of being the best treatment is fairly consistent
with the results for SUCRA for the time independent
measures. However, for non-DTIC, the probability of
being best is lower than SUCRA for the mean at 22 months
relative to the median and expected mean because SUCRA
accounted for the higher probability of non-DTIC being
the second best treatment. Generally, the difference
between DTIC and DTIC + IFN was less pronounced forDTIC + IFN DTIC + non-IFN Non-DTIC
7.87 9.88 10.19
11.41 (8.44, 15.48) 16.11 (11.21, 23.14) 15.31 (9.17, 24.34)








































































Figure 4 Rankograms: Probability plots for competing interventions based on median survival (A), expected survival (B), and mean
survival at 22 months (C).
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http://www.biomedcentral.com/1471-2288/13/147the probability of being the best treatment than for
SUCRA, whereas the difference between DTIC + non-IFN
and non-DTIC was more pronounced for the probability
of being the best than for SUCRA.
The overall pattern for the probability of being the best
treatment and SUCRA are similar for the time-independentand time-varying outcomes (Figure 7), although there were
some differences depending on the specific time-varying
measure. For example, differences between the probability
of being the best treatment and SUCRA for DTIC + non-
IFN and non-DTIC were greatest when based on the































































































































































































































































































































































Figure 5 Probability plots for competing interventions based on hazard (ratio) over time (A), survival proportions over time (B), and
mean survival over time (C).





























































































































































































































DTIC DTIC+IFN DTIC+non-IFN Non-IFN
Solid=Probability of treatment being the best;           Diagonal lines= SUCRA
Figure 6 Probability of being the best treatment and SUCRA for median survival, expected survival, and mean survival at 22 months.
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http://www.biomedcentral.com/1471-2288/13/147Additionally, the initial period where non-DTIC is
expected to be the best treatment is shortest when
based on the HR, longer when based on the survival
function, and longest when based on the mean survival
(up until almost 30 months). A unique feature of the
rankograms based on survival is that the point at which
the probability of being the best treatment switches
from non-DTIC to DTIC + non-IFN is also the time
point when the survival curves cross. As with the
time-independent measures, for all three time-dependent
measures the probability of being the best treatment
suggests that DTIC and DTIC + IFN are comparable
and reflect the two worst treatments, whereas DTIC +
non-IFN appear to be better than non-DTIC. By evalu-
ating SUCRA it is possible to differentiate DTIC and
DTIC + IFN, where a majority of the time points sug-
gest DTIC had a higher proportion than DTIC + IFN.
Moreover, differences between DTIC + non-IFN and
non-DTIC are less dramatic for SUCRA (as opposed to
the probability of being the best treatment), particularly
for mean survival. Overall, SUCRA results may raise
questions about the additional efficacy of IFN in combin-
ation with DTIC as opposed to DITC alone.Discussion
Advantages and disadvantages of different effect
measures in relation to treatment ranking
Table 2 outlines the previously described alternative effect
measures resulting from a NMA of survival data involving
a multi-dimensional treatment effect. While these measures
are all related and based on the same analysis, each meas-
ure involves a different interpretation and slightly different
rank probabilities. Therefore, it is necessary to consider
the advantages and disadvantages associated with each
measure to calculate the rank probabilities.
Time independent measures: median survival, expected
survival, or mean survival at a specific time point?
Median survival provides an intuitive outcome for clini-
cians, which can easily be compared across treatments
and is not very sensitive to parametric modeling assump-
tions. However, the median survival does not capture
survival information beyond the time point at which 50%
of patients have died, thereby providing a limited effect
measure to rank treatments.
Expected survival is the primary measure of interest for



































































































Figure 7 Probability of being best treatment and SUCRA for the hazard (ratio) over time (A), survival proportions over time (B), and
mean survival at subsequent time points (C).
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http://www.biomedcentral.com/1471-2288/13/147this measure may require extrapolation of survival pro-
portions beyond the follow-up of the included studies.
Consequently, rank probabilities base on the expectedsurvival may often rely on extrapolation, possibly to a dif-
ferent extent for each treatment. Also, althoug the estimates
from a parametric model will reflect this uncertainty, the
Table 2 Summary of alternative methods for calculating rank probabilities









Median survival The greatest survival time
when 50% patients are alive
No Yes Yes Commonly used and clinically
relevant; Easily summarized as
statistic; May limit need for
extrapolation;
Ignores what happens after 50% of subjects
have experienced the event;
Expected survival The greatest expected
survival
No Yes Yes Directly relevant for
cost-effectiveness; Easily
summarized as statistic;
Sensitive to tail of distribution (may involve
extrapolation); Does not illustrate time-varying
results or time of greatest treatment effect;
May not be as clinically relevant;
Mean survival at time t Greatest mean survival
(area under the curve)
up until time t
No Yes Yes Limits need for extrapolation
if time t corresponds to
follow-up time of trial with
shortest duration; Easily
summarized as statistic
May be difficult to interpret; Requires subjective
selection of time t; Ignores tails of distribution
and does not illustrate time-varying results;
Hazard (ratio) over time The smallest hazard
(ratio versus reference
treatment) over time
Yes No Yes for
hazard,
Directly relates to model and
may help emphasize changes
in treatment effect over time;
Does not capture cumulative effect of treatment
over time; May lead to over interpretation near
tail of distribution; Cannot be summarized as
statistic (requires graphical illustration); May be









Yes Yes Yes Highly intuitive and clinically
relevant; Can be easily
compared to data;
Cannot be summarized as statistic (requires
graphical illustration);
Mean survival over time Greatest mean survival
(area under the curve)
over time
Yes Yes Yes Reflects a cumulative summary
of survival proportions up until
that time point, thereby
de-emphasizing tail of distribution;
Cannot be summarized as statistic (requires
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lying distribution is not captured, which is an important
consideration [29].
Rank probabilities based on the mean survival at a
specific time point, such as the duration of the trial with
the shortest follow-up, may avoid extrapolation. Therefore
this summary measure may be less sensitive to the
assumptions of extrapolation, although a subjective choice
regarding the time point for analysis is required, which
leaves it open to criticism.
Overall, a summary measure such as the median survival,
expected survival, or mean survival at a specific follow-up
time has the advantage of providing a simple statistic
that does not require graphical presentation over time.
Consequently, rank probabilities based on these effect
measures are therefore easier to interpret and compare
across different analyses than time-varying effect measures.
However, the rank probabilities associated with the one
dimensional effect measures do not capture the possible
time-varying nature of the underlying hazard of dying and
are sensitive to the choice of effect measure.
Time-varying measures: hazard, survival, or mean
survival over time?
Rank probabilities based on the hazard or HR at each time
point reflect the treatment ranking at each time point
independent of previous time points. Presenting the hazard
or HR over time illustrates how treatment effects may vary
over time, which may not be easily detected based on the
corresponding survival curves. However, HR curves may
not be straightforward to interpret and later time points
may be less relevant due to the small proportion of subjects
that remain at risk of dying.
Rank probabilities based on the survival proportions
reflect the cumulative treatment effect of the hazard up
to that point in time. Survival curves can be considered the
most complete and intuitive representation of treatment
effects over time. Presenting survival proportions also
allows the results of the meta-analysis to be compared to
the observed survival curves reported for the individual
studies. Therefore, rank probabilities presented over time
based on survival curves may provide the simplest inter-
pretation and the most ‘face validity’ as compared to
those based on the hazards or HRs over time, especially
considering that decision-makers are likely to be mostly
concerned with actual survival over time, as opposed to
the risk of dying at each time point.
Mean survival at subsequent time points may provide
another measure with value as well for treatment rankings.
By evaluating the area under the curve up to each time
point, as opposed to the actual survival percentages, more
weight is attributed to earlier treatment effects when a
greater proportion of patients are still alive. If two
treatments cross, the treatment with the more favorablesurvival in the beginning will result in a longer period of
being the best treatment if the mean survival is used in
comparison to the survival proportions or the HRs. Em-
phasizing the early treatment effects (and de-emphasizing
later ones) may be considered useful given the increasing
uncertainty in treatment effects over time due to reduced
population at risk and the possible extrapolation of
survival curves.
Overall, rank probabilities of treatment effects over time
may provide a more transparent and informative approach
to help guide decision-making in comparison to single
rank probabilities based on collapsed measures, such as
median survival, or expected survival. Rank probabilities
based on survival proportions may be the most intuitive
and straightforward to communicate, but alternatives based
on the hazard function or mean survival over time may be
useful as well.
Probability of being best treatment, rankograms, or SUCRA?
Summarizing treatment effects and their associated
uncertainty in terms of the probability that each treatment
is best is often presented, although when there is con-
siderable variation in the uncertainty regarding the relative
treatment effects, this approach may lead to false con-
clusions. Rankograms provide the most informative and
balanced approach to translate treatment effects and
their associated uncertainty into probability statements
for decision-making by presenting the probability that
each treatment is best, 2nd best, 3rd best, etc. However,
rankograms become more difficult to interpret for time-
varying treatment effects as compared to one-dimensional
effect measures. In the context of time-varying treatment
effects, graphing SUCRA may provide a more concise
summary measure than presenting all rank probabilities.
Conclusion
In this paper we present different alternatives for quantita-
tive summaries of treatment effect estimates obtained with
NMA of survival data to help inform decision-making.
Rank probabilities based on one-dimensional measures
such as median survival, expected survival, or mean survival
at one follow-up time are relatively easy to understand,
but do not provide the wealth of information captured by
rank probabilities over time. Survival proportions reflect
the cumulative effect of treatments over time and provide
the most intuitive basis for rank probabilities and SUCRA.
Rank probabilities based on the hazard (ratio) function
over time provide information on the treatment effect at
each time point, ignoring effects at previous time points.
Rank probabilities based on the mean survival at each
time point give more weight to the treatment effects when
a greater proportion of patients are alive. Rankograms of
time-varying treatment effects can be presented efficiently
with SUCRA.
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